Bioventus Inc.
BVS
$7.51
-$0.09-1.14%
NASDAQ
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Revenue | 563.83M | 564.14M | 567.70M | 573.28M | 555.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 563.83M | 564.14M | 567.70M | 573.28M | 555.06M |
| Cost of Revenue | 181.80M | 182.79M | 184.80M | 185.05M | 183.19M |
| Gross Profit | 382.03M | 381.35M | 382.90M | 388.23M | 371.87M |
| SG&A Expenses | 317.75M | 320.54M | 325.61M | 330.90M | 322.73M |
| Depreciation & Amortization | 6.20M | 6.87M | 7.49M | 7.65M | 7.99M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 518.10M | 523.47M | 532.21M | 537.54M | 527.85M |
| Operating Income | 45.73M | 40.68M | 35.49M | 35.74M | 27.21M |
| Income Before Tax | 11.80M | 1.87M | -50.00M | -52.06M | -60.70M |
| Income Tax Expenses | 2.16M | 2.09M | -6.30M | -5.29M | -6.59M |
| Earnings from Continuing Operations | 9.64 | -0.22 | -43.71 | -46.76 | -54.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.82M | -283.00K | 10.07M | 10.87M | 12.27M |
| Net Income | 7.82M | -499.00K | -33.64M | -35.89M | -41.83M |
| EBIT | 45.73M | 40.68M | 35.49M | 35.74M | 27.21M |
| EBITDA | 85.83M | 81.65M | 77.51M | 77.68M | 71.07M |
| EPS Basic | 0.12 | -0.01 | -0.52 | -0.56 | -0.65 |
| Normalized Basic EPS | 0.12 | 0.07 | 0.16 | 0.16 | 0.08 |
| EPS Diluted | 0.11 | -0.01 | -0.52 | -0.56 | -0.65 |
| Normalized Diluted EPS | 0.11 | 0.07 | 0.16 | 0.16 | 0.08 |
| Average Basic Shares Outstanding | 264.89M | 263.22M | 260.78M | 258.15M | 255.80M |
| Average Diluted Shares Outstanding | 268.84M | 265.26M | 260.78M | 258.15M | 255.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |